Neurol. praxi. 2020;21(1):21-26 | DOI: 10.36290/neu.2020.022

Botulinum toxin A in the treatment of dystonia

MUDr. Lenka Hvizdošová, MUDr. Pavel Otruba, MBA, MUDr. Martin Nevrlý, Ph.D., prof. MUDr. Petr Kaňovský, CSc.
Neurologická klinika FN a LF UP Olomouc

Botulinum toxin A has been used in the treatment of dystonia since the late 1980s and is the most effective method of treating focal and segmental dystonia, but has also been successfully used in the treatment of other neurological diseases manifesting with involuntary muscle contractions or muscular hypertonicity. The paper presents a summary of current knowledge about dystonia - phenomenology, pathophysiology, clinical picture, classification, and possibilities of therapeutic use of botulinum toxin A with a focus on the treatment of the most common forms of dystonia.

Keywords: dystonia, botulinum toxin A, cervical dystonia.

Published: March 30, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hvizdošová L, Otruba P, Nevrlý M, Kaňovský P. Botulinum toxin A in the treatment of dystonia. Neurol. praxi. 2020;21(1):21-26. doi: 10.36290/neu.2020.022.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, Hallett M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013; 28(7): 863-873. Go to original source... Go to PubMed...
    2. Brin MF, James Ch, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics: Targets and Therapy 2014; 8: 227-241. Go to original source...
    3. Comella CL. Dystonia: Then and now. Parkinsonism Relat Disord 2018; 46(Suppl 1): S66-S69. Go to original source...
    4. Consky ES, Basinski A, Belle L, Ranawaya R, Lang AE. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability. Neurology 1990; 40(Suppl 1): 445.
    5. Consky ES, Lang AE. Clinical assessment of patients with cervical dystonia. Therapy with botulinum toxin 1994: 211-237.
    6. Desrochers P, Brunfeldt A, Sidiropoulos C, Kagerer F. Sensorimotor control in dystonia. Brain Sci 2019; 9(4): 79. Go to original source...
    7. Dressler D, Altenmüller E, Krauss JK. Treatment of dystonia. Cambridge: Cambridge University Press 2018: 20-26, 128-132. Go to original source...
    8. Erro R, Bhatia KP, Espay AJ, Striano P. The epileptic and nonepileptic spectrum of paroxysmal dyskinesias: Channelopathies, synaptopathies, and transportopathies. Mov Disord 2017; 32(3): 310-318. Go to original source... Go to PubMed...
    9. Filip P, Lungu OV, Bareš M. Dystonia and the cerebellum: a new field of interest in movement disorders? Clin Neurophysiol 2013; 124(7): 1269-1276. Go to original source...
    10. Finsterer J, Maeztu C, Revuelta GJ, Reichel G, Truong D. Collum-caput (COL-CAP) concept for conceptual anterocollis, anterocaput, and forward sagittal shift. J Neurol Sci 2015; 355(1-2): 37-43. Go to original source...
    11. Hvizdošová L, Nevrlý M, Otruba P, Hluštík P, Kaňovský P, Zapletalová J. The Prevalence of Dystonic Tremor and Tremor Associated with Dystonia in Patients with Cervical Dystonia. Scientific Reports 2020; in press. Go to original source... Go to PubMed...
    12. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987; 37(4): 616-23. Go to original source... Go to PubMed...
    13. Jost WH, Tatu L. Selection of Muscles for Botulinum Toxin Injections in Cervical Dystonia. Mov Disord Clin Pract 2015; 2(3): 224-226. Go to original source...
    14. Kaňovský P. Dystonia: a disorder of motor programming or motor execution? Mov Disord 2002; 17(6): 1143-7. Go to original source... Go to PubMed...
    15. Kaňovský P, Bhatia KP, Rosales RL. Dystonia and dystonic syndromes. Wien: Springer 2015: 49-60. Go to original source...
    16. Kaňovský P, Rosales RL. Debunking the pathophysiological puzzle of dystonia - with special reference to botulinum toxin therapy. Parkinsonism Relat Disord 2011; 17(Suppl 1): S11-4. Go to original source...
    17. Koizumi H, Goto S, Okita S, Morigaki R, Akaike N, Torii Y, Harakawa T, Ginnaga A, Kaji R. Spinal Central Effects of Peripherally Applied Botulinum Neurotoxin A in Comparison between Its Subtypes A1 and A2. Front Neurol 2014; 5: 98. Go to original source... Go to PubMed...
    18. Lee K, Gu S, Jin L, Le TTN, Cheng LW, Strotmeier J, Kruel AM, Yao G, Perry K, Rummel A, Jin R. Structure of a bimodular botulinum neurotoxin complex provides insights into its oral toxicity. PLoS Pathog 2013; 9(10): e1003690. Go to original source... Go to PubMed...
    19. Nevrlý M, Hluštík P, Hok P, Otruba P, Tüdös Z, Kaňovský P. Changes in sensorimotor network activation after botulinum toxin type A injections in patients with cervical dystonia: a functional MRI study. Exp Brain Res 2018; 236(10): 2627-2637. Go to original source...
    20. Opavský R, Hluštík P, Otruba P, Kaňovský P. Somatosensory cortical activation in cervical dystonia and its modulation with botulinum toxin: an fMRI study. Int J Neurosci 2012; 122(1): 45-52. Go to original source... Go to PubMed...
    21. Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, Kessler KR, Ceballos-Baumann AO, Ohly A, Oertel W, Künig G. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport®. J Neurol Neurosurg Psychiatry 1998; 64: 13-17. Go to original source...
    22. Schneider SA, Bhatia KP. Secondary Dystonia-Clinical Clues and Syndromic Associations. J Mov Disord 2009; 2(2): 58-63. Go to original source...
    23. Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T. The prevalence of primary dystonia: a systemic review and meta-analysis. Mov Disord 2012; 27(14): 1789-96. Go to original source... Go to PubMed...
    24. Tsui JC, Stoessl AJ, Eisen A, Calne S, Calne D. Double- -blind study of botulinum toxin in spasmodic torticollis. Lancet 1986; 328: 245-247. Go to original source...
    25. Yi KH, Choi Yj, Cong L, Lee KL, Hu KS, Kim HJ. Effective botulinum toxin injection guide for treatment of cervical dystonia. Clin Anat 2019. Epub ahead of print. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.